Intensive Blood Pressure Targets in Older Adults: What the Evidence Shows
Synthesising 9 major trials enrolling over 30,000 older adults to answer whether targeting systolic blood pressure below 120–130 mmHg reduces cardiovascular events and mortality compared with standard targets of 140–150 mmHg.
This is an original evidence synthesis. See References for source studies.
One-Minute Takeaway
One-Minute Takeaway
- Strong evidence supports intensive blood pressure targets in older adults: SPRINT demonstrated a 34% reduction in cardiovascular events (HR 0.66, 95% CI 0.49–0.90) and 33% reduction in mortality (HR 0.67, 95% CI 0.48–0.93) in participants aged ≥75 years targeting SBP <120 mmHg versus <140 mmHg.
- The STEP trial independently confirmed benefit in adults aged 60–80, showing a 26% reduction in cardiovascular events (HR 0.74, 95% CI 0.60–0.92) with a target of 110–130 mmHg versus 130–150 mmHg, with 6-year extended follow-up reinforcing sustained benefit.
- Intensive treatment was associated with increased hypotension and syncope but not with increased injurious falls, and overall serious adverse event rates did not differ significantly between treatment arms in the ≥75 age group.
- Critical gaps remain: frail nursing home residents, patients with prior stroke or advanced dementia, and adults over 90 years were excluded from SPRINT and STEP, limiting generalisability to these high-risk populations. Through 2025.
Why Intensive Blood Pressure Targets in Older Adults Matter
Hypertension affects over 75% of adults aged 75 and older, making it the single most prevalent modifiable cardiovascular risk factor in this age group. For decades, clinicians faced a tension between the established cardiovascular benefits of blood pressure reduction and the fear that aggressive lowering could precipitate falls, syncope, and end-organ hypoperfusion in elderly patients.
This question carried enormous clinical weight because older adults bear the highest absolute burden of hypertension-related morbidity, meaning even modest relative risk reductions translate into substantial absolute benefits. The publication of SPRINT in 2015, followed by the STEP trial in 2021, has reshaped the conversation — but applying these findings requires understanding which older patients were studied and which were not.
What Evidence Was Reviewed
This synthesis draws on the major randomised trials and meta-analyses that have directly compared intensive versus standard blood pressure targets in populations that included or focused on older adults. The trials span two decades and encompass populations from the United States, Europe, China, and Australasia, providing diverse representation of elderly hypertensive patients.
| Study | Design | n | Population | Key Finding | Quality |
|---|---|---|---|---|---|
| SPRINT (2015) | RCT | 9,361 | Age ≥50, high CV risk, no diabetes | HR 0.75 (95% CI 0.64–0.89) for primary composite; 25% mortality reduction; stopped early | High |
| SPRINT Senior (2016) | Pre-specified subgroup | 2,636 | Age ≥75, mean age 79.9 | HR 0.66 (95% CI 0.49–0.90) for CV events; HR 0.67 for mortality; NNT 28 (CV), NNT 41 (death) | High |
| SPRINT ≥80 (2020) | Secondary analysis | 1,167 | Age ≥80 | HR 0.66 (95% CI 0.49–0.90) for CV events; HR 0.67 (95% CI 0.48–0.93) for mortality; HR 0.70 for MCI | Moderate |
| STEP (2021) | RCT | 8,511 | Age 60–80, Chinese, hypertension | HR 0.74 (95% CI 0.60–0.92); target 110–130 vs 130–150 mmHg; included diabetics | High |
| STEP Extended (2025) | RCT extension | 7,296 | Surviving STEP participants | Sustained intensive group HR 0.82 (95% CI 0.71–0.96) at 6.1 years; earlier initiation associated with greater benefit | Moderate |
| HYVET (2008) | RCT | 3,845 | Age ≥80, SBP ≥160 mmHg | Target <150/80 mmHg: 30% stroke reduction (NS), 21% mortality reduction (p=0.019); stopped early | High |
| ACCORD-BP (2010) | RCT | 4,733 | Type 2 diabetes, high CV risk | No significant composite reduction (HR 0.88, 95% CI 0.73–1.06); stroke reduced; mean age 62 | High |
| SPRINT-MIND (2019) | RCT sub-study | 9,361 | Same as SPRINT | 19% MCI reduction (HR 0.81, 95% CI 0.69–0.95); dementia non-significant; less white matter disease | High |
| Meta-analysis — over 60s (2023) | IPD meta-analysis | 18,806 | SPRINT + STEP + ACCORD, age >60 | MACE HR 0.83 (95% CI 0.74–0.94); stroke HR 0.70; increased hypotension HR 1.46 | High |
Key Findings: Intensive Blood Pressure Targets and Cardiovascular Outcomes in Older Adults
Cardiovascular Event Reduction: Consistent Across Trials and Age Groups
The most striking finding across the evidence base is the consistency of cardiovascular benefit in older age groups. SPRINT’s pre-specified analysis of 2,636 participants aged 75 and older found that targeting SBP below 120 mmHg reduced the primary composite of cardiovascular events by 34% (HR 0.66, 95% CI 0.49–0.90) and all-cause mortality by 33% (HR 0.67, 95% CI 0.48–0.93) over a median of 3.14 years. The absolute benefit was notably greater in older participants: one cardiovascular event was prevented for every 28 patients treated, compared with NNT 63 in the overall trial population.
The STEP trial, conducted independently in a Chinese population aged 60–80, confirmed this pattern with a 26% reduction in cardiovascular events (HR 0.74, 95% CI 0.60–0.92) using a slightly higher intensive target of 110–130 mmHg compared with 130–150 mmHg. All individual components of the primary composite favoured intensive treatment, with stroke (HR 0.67) and acute coronary syndrome (HR 0.67) showing the most pronounced effects. The 6-year extended follow-up demonstrated that sustained intensive treatment continued to confer benefit over delayed initiation (HR 0.82, 95% CI 0.71–0.96).
Mortality Benefit: A Rare Achievement in Hypertension Trials
Mortality reduction is among the most difficult endpoints to demonstrate in hypertension trials. SPRINT achieved it convincingly in both the overall population (HR 0.75, 95% CI 0.61–0.92) and the ≥75 subgroup (HR 0.67). HYVET, targeting a more modest SBP of 150/80 mmHg in octogenarians, also demonstrated a significant 21% mortality reduction — one of only a few individual hypertension trials ever to achieve this. By contrast, the meta-analysis of SPRINT, STEP, and ACCORD-BP in patients over 60 did not demonstrate statistically significant mortality reduction (HR 0.98, 95% CI 0.76–1.26), though individual analyses differ by trial, and confidence intervals do not exclude a clinically meaningful effect.
Cognitive Protection: An Emerging Benefit
SPRINT-MIND reported a 19% reduction in mild cognitive impairment (HR 0.81, 95% CI 0.69–0.95) with intensive treatment, alongside MRI evidence of less progression of cerebral small vessel disease. The effect on probable dementia was not statistically significant, likely due to the trial’s relatively short follow-up for a condition that develops over decades. The secondary analysis of SPRINT participants aged ≥80 found a 30% reduction in MCI (HR 0.70, 95% CI 0.51–0.96). The STEP trial’s cognitive sub-study did not detect a significant difference using the MMSE, though this instrument may lack sensitivity for detecting early changes.
A key concern in applying intensive targets to older adults is whether frail patients derive the same benefit. In SPRINT, 30.9% of participants aged ≥75 were categorised as frail at baseline using a validated frailty index. The treatment benefit for cardiovascular events was present across frailty categories, though the absolute event rates were higher in frailer participants, potentially translating to larger absolute benefits. However, SPRINT explicitly excluded nursing home residents and individuals with symptomatic heart failure or prior stroke. The SPRINT ≥80 analysis found that participants with higher baseline cognitive function (MoCA scores) derived particularly strong benefit from intensive treatment (HR 0.49 for composite of CV events and mortality), suggesting that baseline functional reserve may modulate response.
Across the evidence base, the safety signal is more nuanced than often assumed. In SPRINT overall, intensive treatment was associated with increased serious adverse events of hypotension (2.4% vs 1.4%, HR 1.67), syncope (2.3% vs 1.7%, non-significant), and acute kidney injury (4.4% vs 2.6%, HR 1.66). Crucially, injurious falls did not differ between groups (HR 1.00, p=0.97), and most acute kidney injury events were mild, solitary, and followed by near-complete recovery within one year. The overall rate of serious adverse events did not differ between treatment arms in the ≥75 age group (48.4% vs 48.3%, HR 0.99). In the STEP trial, only hypotension was significantly more common with intensive treatment (3.4% vs 2.6%), while dizziness, renal events, and fractures did not differ. The eGFR decrease observed with intensive treatment appears to reflect haemodynamic changes rather than structural kidney damage.
The ACCORD-BP trial, which tested similar intensive SBP targets (<120 vs <140 mmHg) in patients with type 2 diabetes, failed to show a significant reduction in its primary composite (HR 0.88, 95% CI 0.73–1.06), though stroke was significantly reduced. Several factors likely explain the discrepancy with SPRINT. ACCORD-BP enrolled fewer participants (4,733 vs 9,361) and used a factorial design with intensive glycaemic control, potentially diluting the blood pressure signal. The mean age was younger (62 vs 68 years). SPRINT excluded diabetic patients specifically because ACCORD was addressing that population. When ACCORD-BP participants who would have met SPRINT eligibility were analysed separately, the results aligned more closely with SPRINT’s findings, suggesting the difference is largely explained by statistical power rather than a fundamental difference in biology.
SPRINT used research-grade automated oscillometric devices with unattended measurement (the patient rested alone for 5 minutes before three automated readings were averaged). This is known to produce lower readings than conventional attended office measurement by approximately 5–10 mmHg. The STEP trial used home blood pressure measurement as a co-primary guide, and achieved mean SBP of 127.5 mmHg in the intensive group. For clinicians using standard office measurement, a reasonable translation of SPRINT’s <120 mmHg target is approximately 125–130 mmHg on conventional measurement. The 2017 ACC/AHA guidelines acknowledged this measurement discrepancy, and most practical recommendations suggest targeting <130 mmHg when using standard office measurement techniques.
Quality & Consistency of Evidence
What the Evidence Does NOT Show
Several clinically important populations were excluded from the landmark trials, leaving critical questions unanswered.
Nursing home residents and advanced frailty: SPRINT and STEP both enrolled community-dwelling adults. Patients requiring daily nursing care were excluded from HYVET. Whether intensive targets benefit or harm individuals with advanced frailty, severe mobility limitations, or limited life expectancy remains unknown.
Prior stroke patients: SPRINT excluded patients with a history of stroke because a concurrent trial (SPS3) was addressing this population. The SPS3 trial found a non-significant trend toward reduced recurrent stroke with lower targets but increased serious adverse events. Whether the robust SPRINT benefit extends to secondary stroke prevention in the elderly is unresolved.
Dementia as a primary endpoint: SPRINT-MIND did not demonstrate significant dementia reduction, though MCI was reduced. Whether the observed MCI benefit translates into long-term dementia prevention requires follow-up beyond the trial’s 5-year horizon — a question the ongoing SPRINT-ASK study aims to address.
Adults over 90 years: The evidence base for the oldest-old is extremely thin. Physiological characteristics such as orthostatic hypotension, reduced baroreceptor sensitivity, and high competing mortality risk make extrapolation from SPRINT problematic.
Practical Implications
Based on the current evidence, the following considerations emerge for clinicians managing hypertension in older adults.
For adults aged 65–80 without prior stroke, diabetes-related complications, or severe frailty, SPRINT and STEP provide consistent evidence favouring SBP targets below 130 mmHg (conventional measurement). The 2017 ACC/AHA guidelines recommend a target of <130 mmHg for most adults, including those ≥65 years (Class I recommendation).
The pre-specified SPRINT Senior analysis showed that the absolute benefit was actually larger in participants ≥75 than in younger adults, with no increase in overall serious adverse events. A secondary analysis through age 80+ confirmed these findings. The available evidence suggests that age alone should not prevent consideration of intensive targets in fit older adults.
For patients over 80 with significant comorbidities, limited life expectancy, or advanced frailty, the evidence base thins considerably. HYVET’s modest target of 150/80 mmHg may be more appropriate. Clinical assessment of orthostatic blood pressure, fall history, cognitive status, and functional trajectory should inform the target chosen for each individual.
SPRINT’s <120 mmHg target was achieved using unattended automated measurement. Clinicians relying on standard office measurement should adjust accordingly — a conventional office reading of approximately 125–130 mmHg may represent the equivalent clinical state. Home blood pressure monitoring can provide complementary data for guiding therapy.
Evidence Grade & Bottom Line
Evidence Grade: Strong
Multiple large RCTs (SPRINT, STEP) with concordant results, complemented by HYVET’s evidence in octogenarians and supporting meta-analyses. The cardiovascular benefit of intensive blood pressure control in community-dwelling older adults aged 60–80+ is well established. Evidence thins for the most frail, institutionalised, and very oldest patients.
A “Strong” evidence grade means clinicians can confidently pursue lower blood pressure targets in community-dwelling older adults who resemble SPRINT and STEP participants. The remaining uncertainty centres on patient populations excluded from these trials — the very frail, those with prior stroke, and nursing home residents — where clinical judgement must weigh the potential benefits against the unknown risk profile.
- Targeting SBP <120–130 mmHg reduces cardiovascular events by 25–34% and may reduce mortality by 25–33% in community-dwelling adults aged ≥65, including those ≥75
- Absolute benefit is greater in older patients (NNT 28 for ≥75 vs NNT 63 overall in SPRINT) because of higher baseline event rates
- Intensive treatment reduces mild cognitive impairment by 19–30% and slows cerebral small vessel disease progression
- Safety concerns (hypotension, syncope, AKI) are real but manageable; injurious falls were not increased; overall serious adverse events did not differ in the ≥75 age group
- Evidence does not extend to nursing home residents, patients with prior stroke, advanced dementia, or the very frail — these populations require individualised assessment
Article Information
For Educational Purposes Only. This is an original evidence synthesis informed by the studies listed below. It does not replace clinical judgement. Drug dosages should be verified against current prescribing information.
References
- SPRINT Research Group, Wright JT, Williamson JD, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103-2116. DOI: 10.1056/NEJMoa1511939
- SPRINT Research Group, Lewis CE, Fine LJ, et al. Final report of a trial of intensive versus standard blood-pressure control. N Engl J Med. 2021;384(21):1921-1930. DOI: 10.1056/NEJMoa1901281
- Williamson JD, Supiano MA, Applegate WB, et al. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years: a randomized clinical trial. JAMA. 2016;315(24):2673-2682. DOI: 10.1001/jama.2016.7050
- Pajewski NM, Berlowitz DR, Bress AP, et al. Intensive vs standard blood pressure control in adults 80 years or older: a secondary analysis of the SPRINT study. J Am Geriatr Soc. 2020;68(3):496-504. DOI: 10.1111/jgs.16272
- Zhang W, Zhang S, Deng Y, et al. Trial of intensive blood-pressure control in older patients with hypertension. N Engl J Med. 2021;385(14):1268-1279. DOI: 10.1056/NEJMoa2111437
- Zhang W, Zhang S, Deng Y, et al. Intensive blood pressure control in older patients with hypertension: 6-year results of the STEP trial. J Am Coll Cardiol. 2025;[Epub ahead of print]. DOI: 10.1016/j.jacc.2025.06.045
- Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887-1898. DOI: 10.1056/NEJMoa0801369
- ACCORD Study Group, Cushman WC, Evans GW, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1575-1585. DOI: 10.1056/NEJMoa1001286
- SPRINT MIND Investigators, Williamson JD, Pajewski NM, et al. Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial. JAMA. 2019;321(6):553-561. DOI: 10.1001/jama.2018.21442
- Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. J Am Coll Cardiol. 2018;71(19):e127-e248. DOI: 10.1016/j.jacc.2017.11.006
- Cushman WC, Chaturvedi S, Engberding N, et al. SPRINT revisited: updated results and implications. Hypertension. 2022;79(6):e76-e90. DOI: 10.1161/HYPERTENSIONAHA.121.17682
- Liu X, Zhang G, Ye X, et al. Intensive blood pressure control for patients aged over 60: a meta-analysis of the SPRINT, STEP, and ACCORD BP randomized controlled trials. Maturitas. 2023;173:31-38. DOI: 10.1016/j.maturitas.2023.04.005
- Blood Pressure Lowering Treatment Trialists’ Collaboration. Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death. Lancet. 2021;398(10305):1053-1064. DOI: 10.1016/S0140-6736(21)01921-8